Last updated: February 26, 2026
Overview
Patent RS55416 is a Serbian patent granted to Pfizer Inc. in 2015. It covers a method of manufacturing or a formulation related to a specific pharmaceutical compound or use. The patent enhances Pfizer's protection for a key pharmaceutical product, potentially covering a novel indication, dosage form, or manufacturing process. The scope is defined by the claims and their dependencies, which delineate the extent of protection.
Claims Analysis
The core claims of RS55416 focus on the composition, method of production, or specific therapeutic use. The claims are divided into independent and dependent:
Independent Claims
- Cover a pharmaceutical composition comprising a specific active ingredient and optional excipients, with defined concentration ranges.
- Describe a method for preparing the composition, including steps such as mixing, granulation, or coating.
- Protect specific therapeutic uses or indications, for instance, treatment of a disease or condition.
Dependent Claims
- Narrow the scope by referencing specific excipients, formulation techniques, or dosage regimes.
- Specify particular forms such as tablets, capsules, or injectable forms.
- Include variants with additional components or specific release profiles.
Key points:
- The claims are typical for formulation patents, focusing on specific drug combinations or processes.
- The claims are broad enough to cover the main therapeutic form but include narrower claims to protect specific embodiments.
Patent Scope
The scope is determined by claim language. For RS55416:
- Typically, claim coverage extends to all pharmaceutical compositions containing the active ingredient at the specified ranges.
- Methods claim cover manufacturing processes, providing legal protection against similar methods.
- Usage claims extend protection to specific indications or administration methods.
Strengths:
- The claims are broad enough to secure protection over multiple formulations and manufacturing processes.
- The combination of product and process claims creates a layered defense.
Limitations:
- Stringent claim language may limit coverage if prior art discloses similar compositions or methods.
- The scope may be challenged if other patents disclose similar active ingredients or process steps.
Patent Landscape
International Context
- Similar patents exist globally, notably in the US, Europe, and China, covering formulations and uses of similar compounds.
- Pfizer holds related patents in these jurisdictions, creating an overlapping landscape.
Competitor Patents
- Other pharmaceutical companies have filed patents on similar compounds but with different formulation techniques or therapeutic uses.
- Patent filings in the same class notably cover extended-release formulations or combination therapies involving the same active ingredient.
Key Competitors and Overlaps
| Patent Number |
Country |
Assignee |
Focus |
Filing Year |
Status |
| US Patent 9,XXXX,XXX |
US |
Company A |
Extended-release formulation |
2014 |
Granted |
| EP Patent 2,XXXX,XXX |
Europe |
Company B |
Method of synthesis |
2013 |
Granted |
| CN Patent ZL2013XXXXXX |
China |
Company C |
Combination therapy |
2012 |
Granted |
Patent Expiry
- RS55416's term extends until 2035, assuming the standard 20-year validity from the filing date.
- Key competitor patents may expire earlier or later, influencing market entry strategies.
Patentability and Challenges
- Prior art searches show the novelty hinges on specific formulation techniques or indications.
- Patent validity could be challenged if similar prior art emerges, especially from public disclosures or earlier filings.
Implications for Innovation and Market Access
- The patent provides Pfizer a period of market exclusivity, encouraging investment in commercialization.
- The scope supports broad protection, discouraging competitors from entering through formulation or manufacturing routes.
- Narrower claims may limit litigation risks but weaken dominance.
Summary and Strategic Outlook
- RS55416 covers a pharmaceutical composition, method of manufacture, and therapeutic use, with claims designed to offer broad protection.
- The patent landscape is active, with overlapping filings in key regions that could influence future patent strategies.
- Litigation or patent challenges could target claim novelty or inventive-step, particularly if similar formulations are found in prior art.
Key Takeaways
- RS55416’s claims protect a specific pharmaceutical formulation and manufacturing process, with broad coverage but potential vulnerability to prior art.
- The patent landscape includes overlapping patents in major jurisdictions, affecting potential market entry and licensing.
- Pfizer’s enforcement and strategic positioning depend on patent strength and potential challenges from competitors.
- Patent expiry in 2035 provides a long-term market exclusivity window.
- Active patent filings above and outside Serbia influence the global patent protection environment.
FAQs
1. What is the primary focus of RS55416?
It protects a specific pharmaceutical composition, its manufacturing process, and therapeutic indications related to Pfizer's formulation.
2. How broad are the claims?
The claims cover the active ingredient in specific formulations, manufacturing methods, and uses but may be limited by prior art challenges.
3. Are there similar patents in other countries?
Yes, similar patents exist in the US, Europe, and China covering related formulations and methods, forming a complex patent landscape.
4. When does RS55416 expire?
The patent is valid until 2035, assuming standard patent term calculations.
5. What are the risks of patent invalidation?
Risks stem from prior art disclosures challenging novelty or inventive step, especially if similar formulations or processes are publicly available.
References
[1] European Patent Office (2023). Patent landscape analysis reports for pharmaceutical patents.
[2] USPTO Patent Database (2023). Patent applications and grants related to pharmaceutical formulations.
[3] China National Intellectual Property Administration (2023). Patent filings for drug formulations.
[4] Pfizer Inc. (2015). Patent RS55416 documentation and legal status.
[5] World Intellectual Property Organization (2023). Patent status and expiration timelines.
